BG62841B1 - Използване на бензидамин за лечение на патологичнисъстояния, причинени от туморнекрозен фактор - Google Patents

Използване на бензидамин за лечение на патологичнисъстояния, причинени от туморнекрозен фактор Download PDF

Info

Publication number: BG62841B1
Authority: BG; Bulgaria
Prior art keywords: benzidamine; acid addition; physiologically acceptable; acceptable acid; tnf
Prior art date: 1993-07-27

Application number

BG100385A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG100385A (bg

Inventor

Valerio Cioli

Original Assignee

Angelini Ricerche S.P.A. Societa'consortile

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-27

Filing date

1996-02-26

Publication date

2000-09-29

1996-02-26 Application filed by Angelini Ricerche S.P.A. Societa'consortile filed Critical Angelini Ricerche S.P.A. Societa'consortile

1996-09-30 Publication of BG100385A publication Critical patent/BG100385A/bg

2000-09-29 Publication of BG62841B1 publication Critical patent/BG62841B1/bg

Links

CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 title claims abstract description 46
229960000333 benzydamine Drugs 0.000 title claims abstract description 23
230000001575 pathological effect Effects 0.000 title claims abstract description 11
150000003839 salts Chemical class 0.000 claims abstract description 15
239000002253 acid Substances 0.000 claims abstract description 14
238000002360 preparation method Methods 0.000 claims abstract description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 32
102000003390 tumor necrosis factor Human genes 0.000 claims description 31
238000000034 method Methods 0.000 claims description 8
208000036142 Viral infection Diseases 0.000 claims description 5
208000015122 neurodegenerative disease Diseases 0.000 claims description 5
208000035143 Bacterial infection Diseases 0.000 claims description 4
206010006895 Cachexia Diseases 0.000 claims description 4
206010040070 Septic Shock Diseases 0.000 claims description 4
208000022362 bacterial infectious disease Diseases 0.000 claims description 4
230000001684 chronic effect Effects 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
201000006417 multiple sclerosis Diseases 0.000 claims description 4
230000036303 septic shock Effects 0.000 claims description 4
208000030507 AIDS Diseases 0.000 claims description 3
206010009900 Colitis ulcerative Diseases 0.000 claims description 3
201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
201000008827 tuberculosis Diseases 0.000 claims description 3
230000003612 virological effect Effects 0.000 claims description 3
230000009385 viral infection Effects 0.000 claims 3
241000894006 Bacteria Species 0.000 claims 1
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 10
241000700159 Rattus Species 0.000 description 6
229960000905 indomethacin Drugs 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
229960001680 ibuprofen Drugs 0.000 description 3
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
WVVCBUGDSFLEHX-UHFFFAOYSA-N Vinigrol Natural products CC(C)C1CCC(C)C2CCC(C)C3(O)C2C(O)C(CO)=CC13 WVVCBUGDSFLEHX-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000000214 mouth Anatomy 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
229960005314 suramin Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
UADXIAKXDDMQEN-VGZBWQSVSA-N vinigrol Chemical compound CC(C)[C@@H]1CC[C@H](C)[C@@H]2C=C(CO)[C@@H](O)[C@H]3[C@]2(O)[C@H](C)CC[C@@H]13 UADXIAKXDDMQEN-VGZBWQSVSA-N 0.000 description 2
YPHMISFOHDHNIV-UHFFFAOYSA-N 4-[2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]piperidine-2,6-dione Chemical compound C1C(C)CC(C)C(=O)C1C(O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-UHFFFAOYSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
201000010927 Mucositis Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229940124642 endogenous agent Drugs 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical class O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
230000000654 trypanocidal effect Effects 0.000 description 1
208000010484 vulvovaginitis Diseases 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
AIDS & HIV (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Separation Of Suspended Particles By Flocculating Agents (AREA)

BG100385A 1993-07-27 1996-02-26 Използване на бензидамин за лечение на патологичнисъстояния, причинени от туморнекрозен фактор BG62841B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT93MI001673A IT1276040B1 (it)	1993-07-27	1993-07-27	Uso della benzidamina nel trattamento di stati patologici causati dal tnf
PCT/EP1994/002343 WO1995003799A1 (en)	1993-07-27	1994-07-14	Use of benzydamine in the treatment of pathological conditions caused by tnf

Publications (2)

Publication Number	Publication Date
BG100385A BG100385A (bg)	1996-09-30
BG62841B1 true BG62841B1 (bg)	2000-09-29

Family

ID=11366694

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG100385A BG62841B1 (bg)	1993-07-27	1996-02-26	Използване на бензидамин за лечение на патологичнисъстояния, причинени от туморнекрозен фактор

Country Status (25)

Country	Link
US (1)	US6300358B1 (de)
EP (1)	EP0711163B1 (de)
JP (1)	JP3587851B2 (de)
CN (1)	CN1085528C (de)
AT (1)	ATE207353T1 (de)
AU (1)	AU692458B2 (de)
BG (1)	BG62841B1 (de)
CA (1)	CA2167926C (de)
CZ (1)	CZ285864B6 (de)
DE (1)	DE69428797T2 (de)
DK (1)	DK0711163T3 (de)
ES (1)	ES2163450T3 (de)
HU (1)	HU226805B1 (de)
IT (1)	IT1276040B1 (de)
LV (1)	LV11524B (de)
NO (1)	NO308195B1 (de)
NZ (1)	NZ269563A (de)
PL (1)	PL312741A1 (de)
PT (1)	PT711163E (de)
RO (1)	RO117149B1 (de)
RU (1)	RU2160102C2 (de)
SI (1)	SI0711163T1 (de)
SK (1)	SK281895B6 (de)
WO (1)	WO1995003799A1 (de)
ZA (1)	ZA945431B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2201736C1 (ru) *	2001-12-24	2003-04-10	Закрытое акционерное общество "Брынцалов-А"	Ушные капли бротинум
CN101199515B (zh) *	2007-12-21	2010-12-08	重庆市莱美药物技术有限公司	盐酸苄达明洗剂及其制备方法
CN102387798A (zh) *	2009-02-10	2012-03-21	细胞基因公司	供治疗、预防和控制结核病的pde4调节剂的使用方法及包含其的组合物
HRP20151393T8 (hr) *	2009-07-08	2016-07-01	Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A.	UPORABA BENZIDAMINA U LIJEČENJU BOLESTI KOJE SU p40-OVISNE
MD4291C1 (ro) *	2013-12-27	2015-02-28	Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова	Preparat medicamentos pentru tratamentul otitelor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1054833A (de) *	1963-08-09
US4980160A (en) *	1986-10-16	1990-12-25	Biogen, Inc.	Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
GB8807803D0 (en) *	1988-03-31	1988-05-05	Glaxo Group Ltd	Biochemical product
IL95031A (en) *	1989-07-18	2007-03-08	Amgen Inc	Method for the production of a human recombinant tumor necrosis factor inhibitor
US5563143A (en) *	1994-09-21	1996-10-08	Pfizer Inc.	Catechol diether compounds as inhibitors of TNF release

1993
- 1993-07-27 IT IT93MI001673A patent/IT1276040B1/it active IP Right Grant
1994
- 1994-07-14 JP JP50552795A patent/JP3587851B2/ja not_active Expired - Fee Related
- 1994-07-14 RU RU96105062/14A patent/RU2160102C2/ru active
- 1994-07-14 AU AU73861/94A patent/AU692458B2/en not_active Expired
- 1994-07-14 NZ NZ269563A patent/NZ269563A/en not_active IP Right Cessation
- 1994-07-14 AT AT94923739T patent/ATE207353T1/de active
- 1994-07-14 ES ES94923739T patent/ES2163450T3/es not_active Expired - Lifetime
- 1994-07-14 PL PL94312741A patent/PL312741A1/xx unknown
- 1994-07-14 US US08/586,804 patent/US6300358B1/en not_active Expired - Lifetime
- 1994-07-14 WO PCT/EP1994/002343 patent/WO1995003799A1/en not_active Ceased
- 1994-07-14 SK SK105-96A patent/SK281895B6/sk not_active IP Right Cessation
- 1994-07-14 SI SI9430373T patent/SI0711163T1/xx unknown
- 1994-07-14 DE DE69428797T patent/DE69428797T2/de not_active Expired - Lifetime
- 1994-07-14 RO RO96-00144A patent/RO117149B1/ro unknown
- 1994-07-14 EP EP94923739A patent/EP0711163B1/de not_active Expired - Lifetime
- 1994-07-14 HU HU9600182A patent/HU226805B1/hu unknown
- 1994-07-14 CA CA002167926A patent/CA2167926C/en not_active Expired - Lifetime
- 1994-07-14 PT PT94923739T patent/PT711163E/pt unknown
- 1994-07-14 CZ CZ96255A patent/CZ285864B6/cs not_active IP Right Cessation
- 1994-07-14 DK DK94923739T patent/DK0711163T3/da active
- 1994-07-22 ZA ZA945431A patent/ZA945431B/xx unknown
1996
- 1996-01-26 NO NO960347A patent/NO308195B1/no not_active IP Right Cessation
- 1996-02-15 LV LVP-96-46A patent/LV11524B/en unknown
- 1996-02-26 BG BG100385A patent/BG62841B1/bg unknown
- 1996-07-14 CN CN94193377A patent/CN1085528C/zh not_active Expired - Lifetime

Also Published As

Publication number	Publication date
IT1276040B1 (it)	1997-10-24
LV11524B (en)	1996-12-20
AU692458B2 (en)	1998-06-11
CZ285864B6 (cs)	1999-11-17
EP0711163A1 (de)	1996-05-15
SK281895B6 (sk)	2001-09-11
NZ269563A (en)	2001-03-30
DE69428797T2 (de)	2002-04-18
SK10596A3 (en)	1997-03-05
WO1995003799A1 (en)	1995-02-09
ATE207353T1 (de)	2001-11-15
JPH09500385A (ja)	1997-01-14
ITMI931673A0 (it)	1993-07-27
DE69428797D1 (de)	2001-11-29
CA2167926A1 (en)	1995-02-09
HUT73500A (en)	1996-08-28
PL312741A1 (en)	1996-05-13
CN1085528C (zh)	2002-05-29
ZA945431B (en)	1995-02-28
JP3587851B2 (ja)	2004-11-10
NO960347L (no)	1996-03-07
EP0711163B1 (de)	2001-10-24
LV11524A (lv)	1996-10-20
SI0711163T1 (en)	2001-12-31
NO308195B1 (no)	2000-08-14
ES2163450T3 (es)	2002-02-01
ITMI931673A1 (it)	1995-01-27
CA2167926C (en)	2004-12-21
NO960347D0 (no)	1996-01-26
RO117149B1 (ro)	2001-11-30
PT711163E (pt)	2002-04-29
CZ25596A3 (en)	1996-07-17
US6300358B1 (en)	2001-10-09
BG100385A (bg)	1996-09-30
RU2160102C2 (ru)	2000-12-10
AU7386194A (en)	1995-02-28
HU226805B1 (en)	2009-10-28
DK0711163T3 (da)	2001-11-26
CN1130872A (zh)	1996-09-11

Publication	Publication Date	Title
US6291527B1 (en)	2001-09-18	Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application
US20060111428A1 (en)	2006-05-25	Combination of an dpp-iv inhibitor and a ppar-alpha compound
JPH03181422A (ja)	1991-08-07	炎症の治療方法及び炎症の治療用合成薬
KR100322042B1 (ko)	2002-11-04	비쇼그렌증후군성구강건조증치료제
EP0491018A1 (de)	1992-06-24	Verwendung von taurolidin und/oder taurultam zur behandlung von tumoren
SK7502002A3 (en)	2003-02-04	Pharmaceutical combinations
EP0923371A1 (de)	1999-06-23	Pharmazeutische zusammensetzungen enthaltend tyrphostine
ZA200105275B (en)	2002-09-26	New use of melagatran.
BG62841B1 (bg)	2000-09-29	Използване на бензидамин за лечение на патологичнисъстояния, причинени от туморнекрозен фактор
JPH10511978A (ja)	1998-11-17	アルツハイマー病の治療用薬剤
Valeriano-Marcet et al.	1991	Myonecrosis and myofibrosis as complications of sickle cell anemia
ZA200106199B (en)	2002-03-06	Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity.
KR100851938B1 (ko)	2008-08-12	방광 질환의 치료를 위한 카프-오피에이트 작용제
FI105075B (fi)	2000-06-15	Kombinaatioinjektiovalmisteen käyttö
KR100514009B1 (ko)	2005-11-25	1,2,4-벤조트리아진옥사이드제제
EP0551180B1 (de)	1994-12-28	Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria
HUP0203790A2 (hu)	2003-04-28	(6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére
EP0256629A2 (de)	1988-02-24	Tolrestat oder ein Salz davon als immun-stimulierendes Mittel
KR100508623B1 (ko)	2005-08-17	마크롤라이드 화합물의 신규한 용도
US6693100B1 (en)	2004-02-17	Pharmaceutical compositions for treating psoriasis
SK2802002A3 (en)	2003-02-04	The use of dexrazoxane, an article comprising dexrazoxane, method for treating psoriasis and method for producing a drug